DNA Damage Responses in Tumors Are Not Proliferative Stimuli but Rather They Are DNA Repair Actions Requiring Supportive Medical Care
Preprint
- 7 March 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background In tumors, somatic mutagenesis presumably drives DNA damage response (DDR) via altered regulatory pathways increasing genomic instability and proliferative activity. These considerations led to the standard therapeutic strategy against cancer: the disruption of mutation activated DNA repair pathways of tumors. Purpose Justifying that cancer cells are not enemies to be killed, but rather they are ill human cells having the remnants of physiologic regulatory pathways. Results 1. Genomic instability and cancer development may be originated from the flaw of estrogen signal rather than excessive estrogen signaling. 2. Healthy cells with genomic instability exhibit somatic mutations helping DNA restitution. 3. Somatic mutations in tumor cells aim the restoration of DNA damage rather than further genomic derangement. 4. In tumors, estrogen signal drives the pathways of DNA stabilization leading to apoptotic death. 5. In the peritumoral cellular infiltration, the genomic damage of tumor induces inflammatory cytokine secretion and increased estrogen synthesis. In the inflammatory cells, increased growth factor receptor (GFR) signal confers unliganded activation of estrogen receptors (ERs). 6. In tumor cells responsive to genotoxic therapy, constitutive mutations help the upregulation of estrogen signal and consequential apoptosis. In tumors non responsive to genotoxic therapy, the possibilities for ER activation via either liganded or unliganded pathway, are exhausted leading to farther genomic instability and unrestrained proliferation. Conclusion Understanding the real character and behavior of human tumors at molecular level suggests that we should learn the genome repairing methods of tumors and follow them by supportive therapy rather than provoking additional genomic damages.Keywords
All Related Versions
- Version 1, 2024-03-07, Preprints
- Published version: Cancers, 16 (8), 1573.
This publication has 169 references indexed in Scilit:
- Role of tumor microenvironment in cancer progression and therapeutic strategyCancer Medicine, 2023
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical TrialsJAMA, 2020
- Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics eraFEBS Letters, 2020
- HER2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a French regional cohortCancer Medicine, 2014
- Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non–clinic‐based sample of women in northern CaliforniaCancer, 2013
- Mechanism of metabolic activation and DNA adduct formation by the human carcinogen diethylstilbestrol: The defining link to natural estrogensInternational Journal of Cancer, 2008
- The secretory function of adipocytes in the physiology of white adipose tissueJournal of Cellular Physiology, 2008
- Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone‐dependent breast cancer cellsJournal of Cellular Biochemistry, 2002
- Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell linesInternational Journal of Cancer, 2000
- Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.The EMBO Journal, 1996